Discover which therapies are expected to grab the HER2-low cancers market share @ HER2-low Cancers Market Report The HER2-low ...

I maintain a Buy rating on Zymeworks Inc. stock due to platform promise and upcoming catalysts. However, click for why I am ...

HER2+ Gastric Cancer Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the ...

Survival outcomes for people with HER2-positive breast cancer, once seen as an aggressive type of the disease, have been transformed through the development of targeted therapies, including Roche ...

In the study, 270 patients with metastatic HR/HER2–positive breast cancer receiving a first to third line of treatment were randomized to one of two arms. In the chemotherapy arm, patients received ...

Accord BioPharma announced that the FDA has approved Hercessi (trastuzumab-strf), a biosimilar to Herceptin (trastuzumab), for the treatment of human epidermal growth factor receptor 2 ...

Find out all you need to know about Herceptin (trastuzumab) for early and more advanced HER2-positive breast cancer, including what to expect, outcomes, side effects, and more.

Herceptin is a prescription drug used to treat certain kinds of breast and stomach cancer in adults. Learn about side effects and what to do about them. ... HER2-positive breast cancer; gastric ...

Herceptin’s long-lasting dominance of the gastroesophageal cancer market may be under threat. At the European Society of Medical Oncology Congress 2021, Zymeworks presented encouraging early ...

Herceptin (or trastuzumab), a humanized anti-HER2 monoclonal antibody (Ab), is an effective HER2-targeted therapy against early and metastatic HER2-positive breast cancers.

Basel, 23 December 2020– Roche today announced that the European Commission has approved Phesgo ®, a fixed-dose combination of Perjeta ® and Herceptin ® with hyaluronidase, administered by ...

Herceptin is used to treat HER2 positive breast cancer, but side effects include heart damage. A new study finds that treating women with chemotherapy before or while giving Herceptin reduces damage.